Do analysts prefer EVAX or CELZ?

Evaxion A/S currently has a consensus price target of $11.00, indicating a potential upside of 251.44%. Given Evaxion A/S's stronger consensus rating and higher possible upside, equities analysts plainly believe Evaxion A/S is more favorable than Creative Medical Technology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evaxion A/S 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Creative Medical Technology 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is EVAX or CELZ more profitable?

Evaxion A/S's return on equity of -61.43% beat Creative Medical Technology's return on equity. Company Net Margins Return on Equity Return on Assets Evaxion A/S N/A -61.43% -34.23% Creative Medical Technology N/A -86.52% -81.96%

Does the media prefer EVAX or CELZ?

In the previous week, Evaxion A/S and Evaxion A/S both had 3 articles in the media. Creative Medical Technology's average media sentiment score of 0.97 beat Evaxion A/S's score of 0.43 indicating that Creative Medical Technology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evaxion A/S 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Creative Medical Technology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer ATOS or CELZ?

Atossa Genetics presently has a consensus price target of $20.33, indicating a potential upside of 710.09%. Given Atossa Genetics' stronger consensus rating and higher possible upside, equities analysts clearly believe Atossa Genetics is more favorable than Creative Medical Technology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atossa Genetics 2 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20 Creative Medical Technology 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is ATOS or CELZ more profitable?

Creative Medical Technology's return on equity of -86.52% beat Atossa Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Atossa Genetics N/A -102.99% -85.78% Creative Medical Technology N/A -86.52% -81.96%

Do analysts rate JSPR or CELZ?

Jasper Therapeutics currently has a consensus target price of $8.17, suggesting a potential upside of 1,136.81%. Given Jasper Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Jasper Therapeutics is more favorable than Creative Medical Technology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jasper Therapeutics 1 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.50 Creative Medical Technology 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is JSPR or CELZ more profitable?

Creative Medical Technology's return on equity of -86.52% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Jasper Therapeutics N/A -884.17% -143.83% Creative Medical Technology N/A -86.52% -81.96%

Do analysts rate CELZ or LTRN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Creative Medical Technology 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CELZ or LTRN more profitable?

Creative Medical Technology's return on equity of -86.52% beat Lantern Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Creative Medical Technology N/A -86.52% -81.96% Lantern Pharma N/A -368.02% -148.62%

Do analysts recommend TCRX or CELZ?

TScan Therapeutics currently has a consensus target price of $2.67, suggesting a potential upside of 732.29%. Given TScan Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe TScan Therapeutics is more favorable than Creative Medical Technology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TScan Therapeutics 1 Sell rating(s) 5 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.13 Creative Medical Technology 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media refer more to TCRX or CELZ?

In the previous week, TScan Therapeutics had 7 more articles in the media than Creative Medical Technology. MarketBeat recorded 10 mentions for TScan Therapeutics and 3 mentions for Creative Medical Technology. Creative Medical Technology's average media sentiment score of 0.97 beat TScan Therapeutics' score of 0.57 indicating that Creative Medical Technology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TScan Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Creative Medical Technology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Creative Medical Technology (CELZ) Competitors

$0.96 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$0.97 +0.01 (+0.77%)

As of 08:24 AM Eastern

Compare

CELZ vs. EVAX, ATOS, JSPR, LTRN, and TCRX

Should you buy Creative Medical Technology stock or one of its competitors? Creative Medical Technology's main competitors and comparable companies include Evaxion A/S (EVAX), Atossa Genetics (ATOS), Jasper Therapeutics (JSPR), Lantern Pharma (LTRN), and TScan Therapeutics (TCRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Creative Medical Technology compare to Evaxion A/S?

Evaxion A/S (NASDAQ:EVAX) and Creative Medical Technology (NASDAQ:CELZ) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

Evaxion A/S currently has a consensus price target of $11.00, indicating a potential upside of 251.44%. Given Evaxion A/S's stronger consensus rating and higher possible upside, equities analysts plainly believe Evaxion A/S is more favorable than Creative Medical Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Creative Medical Technology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

11.0% of Evaxion A/S shares are held by institutional investors. Comparatively, 1.4% of Creative Medical Technology shares are held by institutional investors. 41.6% of Evaxion A/S shares are held by company insiders. Comparatively, 1.0% of Creative Medical Technology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Creative Medical Technology has lower revenue, but higher earnings than Evaxion A/S. Evaxion A/S is trading at a lower price-to-earnings ratio than Creative Medical Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion A/S	$7.53M	3.47	-$7.71M	-$1.21	N/A
Creative Medical Technology	$10K	633.04	-$5.99M	-$2.07	N/A

In the previous week, Evaxion A/S and Evaxion A/S both had 3 articles in the media. Creative Medical Technology's average media sentiment score of 0.97 beat Evaxion A/S's score of 0.43 indicating that Creative Medical Technology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evaxion A/S	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Creative Medical Technology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Evaxion A/S has a beta of 0.26, indicating that its share price is 74% less volatile than the broader market. Comparatively, Creative Medical Technology has a beta of 2.04, indicating that its share price is 104% more volatile than the broader market.

Evaxion A/S's return on equity of -61.43% beat Creative Medical Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evaxion A/S	N/A	-61.43%	-34.23%
Creative Medical Technology	N/A	-86.52%	-81.96%

Summary

Evaxion A/S beats Creative Medical Technology on 9 of the 14 factors compared between the two stocks.

How does Creative Medical Technology compare to Atossa Genetics?

Atossa Genetics (NASDAQ:ATOS) and Creative Medical Technology (NASDAQ:CELZ) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment.

12.7% of Atossa Genetics shares are held by institutional investors. Comparatively, 1.4% of Creative Medical Technology shares are held by institutional investors. 9.8% of Atossa Genetics shares are held by company insiders. Comparatively, 1.0% of Creative Medical Technology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Creative Medical Technology's return on equity of -86.52% beat Atossa Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atossa Genetics	N/A	-102.99%	-85.78%
Creative Medical Technology	N/A	-86.52%	-81.96%

Atossa Genetics has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market. Comparatively, Creative Medical Technology has a beta of 2.04, meaning that its stock price is 104% more volatile than the broader market.

Creative Medical Technology has higher revenue and earnings than Atossa Genetics. Atossa Genetics is trading at a lower price-to-earnings ratio than Creative Medical Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atossa Genetics	N/A	N/A	-$34.77M	-$3.11	N/A
Creative Medical Technology	$10K	633.04	-$5.99M	-$2.07	N/A

In the previous week, Creative Medical Technology had 2 more articles in the media than Atossa Genetics. MarketBeat recorded 3 mentions for Creative Medical Technology and 1 mentions for Atossa Genetics. Atossa Genetics' average media sentiment score of 1.87 beat Creative Medical Technology's score of 0.97 indicating that Atossa Genetics is being referred to more favorably in the media.

Company	Overall Sentiment
Atossa Genetics	Very Positive
Creative Medical Technology	Positive

Atossa Genetics presently has a consensus price target of $20.33, indicating a potential upside of 710.09%. Given Atossa Genetics' stronger consensus rating and higher possible upside, equities analysts clearly believe Atossa Genetics is more favorable than Creative Medical Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Creative Medical Technology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Creative Medical Technology beats Atossa Genetics on 8 of the 14 factors compared between the two stocks.

How does Creative Medical Technology compare to Jasper Therapeutics?

Jasper Therapeutics (NASDAQ:JSPR) and Creative Medical Technology (NASDAQ:CELZ) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

In the previous week, Creative Medical Technology had 1 more articles in the media than Jasper Therapeutics. MarketBeat recorded 3 mentions for Creative Medical Technology and 2 mentions for Jasper Therapeutics. Creative Medical Technology's average media sentiment score of 0.97 beat Jasper Therapeutics' score of 0.94 indicating that Creative Medical Technology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jasper Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Creative Medical Technology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Creative Medical Technology has higher revenue and earnings than Jasper Therapeutics. Creative Medical Technology is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jasper Therapeutics	N/A	N/A	-$75.80M	-$1.59	N/A
Creative Medical Technology	$10K	633.04	-$5.99M	-$2.07	N/A

79.9% of Jasper Therapeutics shares are owned by institutional investors. Comparatively, 1.4% of Creative Medical Technology shares are owned by institutional investors. 3.9% of Jasper Therapeutics shares are owned by insiders. Comparatively, 1.0% of Creative Medical Technology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Jasper Therapeutics currently has a consensus target price of $8.17, suggesting a potential upside of 1,136.81%. Given Jasper Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Jasper Therapeutics is more favorable than Creative Medical Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Creative Medical Technology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Creative Medical Technology's return on equity of -86.52% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jasper Therapeutics	N/A	-884.17%	-143.83%
Creative Medical Technology	N/A	-86.52%	-81.96%

Jasper Therapeutics has a beta of 3.04, meaning that its share price is 204% more volatile than the broader market. Comparatively, Creative Medical Technology has a beta of 2.04, meaning that its share price is 104% more volatile than the broader market.

Summary

Jasper Therapeutics beats Creative Medical Technology on 8 of the 14 factors compared between the two stocks.

How does Creative Medical Technology compare to Lantern Pharma?

Creative Medical Technology (NASDAQ:CELZ) and Lantern Pharma (NASDAQ:LTRN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.

Creative Medical Technology has higher revenue and earnings than Lantern Pharma. Lantern Pharma is trading at a lower price-to-earnings ratio than Creative Medical Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Creative Medical Technology	$10K	633.04	-$5.99M	-$2.07	N/A
Lantern Pharma	N/A	N/A	-$17.12M	-$1.62	N/A

Creative Medical Technology's return on equity of -86.52% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Creative Medical Technology	N/A	-86.52%	-81.96%
Lantern Pharma	N/A	-368.02%	-148.62%

1.4% of Creative Medical Technology shares are owned by institutional investors. Comparatively, 28.6% of Lantern Pharma shares are owned by institutional investors. 1.0% of Creative Medical Technology shares are owned by insiders. Comparatively, 8.5% of Lantern Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Creative Medical Technology had 2 more articles in the media than Lantern Pharma. MarketBeat recorded 3 mentions for Creative Medical Technology and 1 mentions for Lantern Pharma. Lantern Pharma's average media sentiment score of 1.87 beat Creative Medical Technology's score of 0.97 indicating that Lantern Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Creative Medical Technology	Positive
Lantern Pharma	Very Positive

Creative Medical Technology has a beta of 2.04, suggesting that its share price is 104% more volatile than the broader market. Comparatively, Lantern Pharma has a beta of 2.3, suggesting that its share price is 130% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Creative Medical Technology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Creative Medical Technology beats Lantern Pharma on 8 of the 13 factors compared between the two stocks.

How does Creative Medical Technology compare to TScan Therapeutics?

TScan Therapeutics (NASDAQ:TCRX) and Creative Medical Technology (NASDAQ:CELZ) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations.

In the previous week, TScan Therapeutics had 7 more articles in the media than Creative Medical Technology. MarketBeat recorded 10 mentions for TScan Therapeutics and 3 mentions for Creative Medical Technology. Creative Medical Technology's average media sentiment score of 0.97 beat TScan Therapeutics' score of 0.57 indicating that Creative Medical Technology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TScan Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Creative Medical Technology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TScan Therapeutics has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market. Comparatively, Creative Medical Technology has a beta of 2.04, indicating that its share price is 104% more volatile than the broader market.

Creative Medical Technology has lower revenue, but higher earnings than TScan Therapeutics. Creative Medical Technology is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TScan Therapeutics	$10.32M	2.10	-$129.77M	-$0.91	N/A
Creative Medical Technology	$10K	633.04	-$5.99M	-$2.07	N/A

Creative Medical Technology has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,655.35%. Creative Medical Technology's return on equity of -86.52% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TScan Therapeutics	-1,655.35%	-108.72%	-54.47%
Creative Medical Technology	N/A	-86.52%	-81.96%

TScan Therapeutics currently has a consensus target price of $2.67, suggesting a potential upside of 732.29%. Given TScan Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe TScan Therapeutics is more favorable than Creative Medical Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TScan Therapeutics	1 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.13
Creative Medical Technology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

82.8% of TScan Therapeutics shares are owned by institutional investors. Comparatively, 1.4% of Creative Medical Technology shares are owned by institutional investors. 6.3% of TScan Therapeutics shares are owned by insiders. Comparatively, 1.0% of Creative Medical Technology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

TScan Therapeutics beats Creative Medical Technology on 10 of the 16 factors compared between the two stocks.

Get Creative Medical Technology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CELZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CELZ vs. The Competition

Export

Metric	Creative Medical Technology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.33M	$3.84B	$7.15B	$12.84B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	-0.46	14.25	275.24	25.35
Price / Sales	633.04	1,424.44	647.32	90.72
Price / Cash	N/A	43.64	28.42	34.96
Price / Book	0.47	15.12	10.33	6.21
Net Income	-$5.99M	-$22.86M	$3.50B	$358.54M
7 Day Performance	-13.46%	-4.36%	-3.32%	-2.39%
1 Month Performance	-21.26%	-0.65%	-0.87%	-3.39%
1 Year Performance	-72.55%	40.76%	23.52%	8.81%

Creative Medical Technology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CELZ Creative Medical Technology	1.6925 of 5 stars	$0.96 flat	N/A	-72.6%	$6.33M	$10K	N/A	5	Analyst Upgrade Short Interest Decrease
EVAX Evaxion A/S	1.9585 of 5 stars	$3.11 -5.6%	$11.00 +254.3%	+6.5%	$25.90M	$7.53M	N/A	60	Short Interest Increase
ATOS Atossa Genetics	2.563 of 5 stars	$2.40 +0.0%	$20.33 +746.9%	-80.1%	$24.20M	N/A	N/A	8	Positive News Gap Down
JSPR Jasper Therapeutics	2.1023 of 5 stars	$0.72 +2.0%	$8.17 +1,042.2%	-72.8%	$23.66M	N/A	N/A	20	Gap Up
LTRN Lantern Pharma	0.8841 of 5 stars	$1.78 +0.6%	N/A	-55.4%	$22.74M	N/A	N/A	20	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CELZ) was last updated on 9/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Creative Medical Technology (CELZ) Competitors

CELZ vs. EVAX, ATOS, JSPR, LTRN, and TCRX

How does Creative Medical Technology compare to Evaxion A/S?

Summary

How does Creative Medical Technology compare to Atossa Genetics?

Summary

How does Creative Medical Technology compare to Jasper Therapeutics?

Summary

How does Creative Medical Technology compare to Lantern Pharma?

Summary

How does Creative Medical Technology compare to TScan Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELZ vs. The Competition

Creative Medical Technology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Creative Medical Technology (CELZ) Competitors

CELZ vs. EVAX, ATOS, JSPR, LTRN, and TCRX

How does Creative Medical Technology compare to Evaxion A/S?

Do analysts prefer EVAX or CELZ?

Do insiders & institutionals hold more shares of EVAX or CELZ?

Which has preferable valuation and earnings, EVAX or CELZ?

Does the media prefer EVAX or CELZ?

Which has more volatility and risk, EVAX or CELZ?

Is EVAX or CELZ more profitable?

Summary

How does Creative Medical Technology compare to Atossa Genetics?

Do insiders & institutionals believe in ATOS or CELZ?

Is ATOS or CELZ more profitable?

Which has more volatility and risk, ATOS or CELZ?

Which has better valuation and earnings, ATOS or CELZ?

Does the media refer more to ATOS or CELZ?

Do analysts prefer ATOS or CELZ?

Summary

How does Creative Medical Technology compare to Jasper Therapeutics?

Does the media refer more to JSPR or CELZ?

Which has preferable earnings & valuation, JSPR or CELZ?

Do insiders & institutionals hold more shares of JSPR or CELZ?

Do analysts rate JSPR or CELZ?

Is JSPR or CELZ more profitable?

Which has more risk and volatility, JSPR or CELZ?

Summary

How does Creative Medical Technology compare to Lantern Pharma?

Which has higher earnings and valuation, CELZ or LTRN?

Is CELZ or LTRN more profitable?

Do institutionals and insiders hold more shares of CELZ or LTRN?

Does the media favor CELZ or LTRN?

Which has more volatility and risk, CELZ or LTRN?

Do analysts rate CELZ or LTRN?

Summary

How does Creative Medical Technology compare to TScan Therapeutics?

Does the media refer more to TCRX or CELZ?

Which has more volatility and risk, TCRX or CELZ?

Which has better earnings & valuation, TCRX or CELZ?

Is TCRX or CELZ more profitable?

Do analysts recommend TCRX or CELZ?

Do institutionals & insiders have more ownership in TCRX or CELZ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELZ vs. The Competition

Creative Medical Technology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools